Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|December 1, 1993
Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agentsA LLerena, A G Herraíz, J Cobaleda, et al.
Scientific Reports|July 10, 2025
CYP2D6-inhibiting drugs and risk of fall injury after newly initiated therapy with beta-blockers-a register-based case-crossover studyKarin Leander, M-L Dahl, M Vikström, et al.
Clinical Pharmacology and Therapeutics|July 1, 1989
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beingsM L Dahl-Puustinen, A Lidén, C Alm, et al.
Acta Psychiatrica Scandinavica|December 12, 1997
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitorsO Spigset, K Hedenmalm, M L Dahl, et al.
Pharmacogenetics|January 14, 2000
Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genesP Dalén, M L Dahl, M Eichelbaum, et al.
Pharmacology & Toxicology|May 1, 1996
Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian populationT Marandi, M L Dahl, R A Kiivet, et al.
Journal of Clinical Psychopharmacology|December 31, 1997
The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patientsK Mihara, K Otani, G Tybring, et al.
European Journal of Clinical Pharmacology|October 17, 1998
CYP2D6 and CYP2C19 genotypes in an elderly Swedish populationH Yamada, M L Dahl, L Lannfelt, et al.
Clinical Pharmacology and Therapeutics|January 1, 1992
Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish populationM L Dahl, I Johansson, M P Palmertz, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxinM O Magnusson, M-L Dahl, J Cederberg, et al.
Pageof 11